Latest / Raleigh News Today | 2 Min News | The Daily News Now!
J&J’s Earnings Dip Signals Big Bets | Raleigh News
Johnson & Johnson just slashed its 2026 earnings forecast — a move that might sound bad, but it’s actually a sign they’re betting big on future science. Recent acquisitions like Sail Biomedicines could cost them $1.36 per share in 2027, mostly if they buy out Sail entirely — and that’s not a bad thing. The company’s revenue outlook remains strong, but they’re pouring billions into next-gen therapies, like in-house CAR-T tech. A bigger short-term hit? Maybe. But it could mean a massive payoff down the road — or a strategic retreat if the science doesn’t deliver. This isn’t about today’s…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.